Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status

A 36-year-old transgenderman (assigned female at birth) on exogenous testosterone therapywas found to have stage IIA ovarian endometrioid carcinoma, and underwent adjuvant chemotherapy. Diffuse androgen receptor expression in the tumor initiated amultidisciplinary discussion regarding the safety of continuing exogenous testosterone as gender-affirming hormone therapy. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

A 36-year-old transgender man with stage IIA ovarian endometrioid carcinoma raised concerns about the safety of continuing exogenous testosterone therapy. The diffuse androgen receptor expression in the tumor prompted a multidisciplinary discussion.